SOUTH SAN FRANCISCO, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced upcoming data and corporate presentations. Voreloxin mechanism of action data and interim data from the company's ongoing Phase 1 clinical trial of SNS-314 in patients with advanced solid tumors will be presented at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics." Updated interim data from Sunesis' ongoing Phase 2 clinical trial of voreloxin in platinum-resistant ovarian cancer patients will be presented during the 12th Biennial Meeting International Gynecologic Cancer Society. Sunesis will also present a corporate presentation at the BIO Investor Forum. Following are the details on each of these presentations.
EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland
12th Biennial Meeting International Gynecologic Cancer Society, Bangkok, Thailand
Interested parties may access a webcast of the BIO Investor Forum presentation by visiting the Sunesis website at http://ir.sunesis.com. A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.
About Voreloxin
Voreloxin is a first-in-class naphthyridine analog, a chemical structure closely related to that of the quinolone antibacterial agents. Voreloxin exerts potent anti-cancer activity through a mechanism that involves intercalation into DNA and an inhibition of topoisomerase II activity that results in replication-dependent, site-selective double-strand breaks in DNA followed by G2 arrest and apoptosis. Voreloxin is currently being evaluated as a single agent in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly patients with acute myeloid leukemia (AML), in a Phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, and as a single agent in a Phase 2 clinical trial in platinum-resistant ovarian cancer. In clinical trials conducted to date, voreloxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types.
About SNS-314
SNS-314, a potent and selective pan-Aurora kinase inhibitor, is being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors.
About Sunesis Pharmaceuticals
Sunesis is a clinical-stage biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.
SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.
CONTACT: Eric Bjerkholt of Sunesis Pharmaceuticals, Inc., +1-650-266-3717;
or Media, Monique Greer of Invigorate Communications, +1-415-946-1075
Web site: http://www.sunesis.com/
